GERON CORP Realized Investment Gains (Losses)
GERON CORP (GERN) reported Realized Investment Gains (Losses) of $1.23 million for the 3-month period ending 2021-03-31, per its 10-K filed 2024-02-28.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:RealizedInvestmentGainsLosses · last filed 2024-02-28
- GERON CORP realized investment gains (losses) for the quarter ending 2021-03-31 was $1.23M.
- GERON CORP realized investment gains (losses) for the quarter ending 2020-09-30 was -$34.00K.
| Period end | Realized Investment Gains (Losses) 0 month | Realized Investment Gains (Losses) 3 month |
|---|---|---|
| 2021-03-31 | $1.23M 10-K · filed 2024-02-28 | |
| 2020-09-30 | -$34.00K 10-K · filed 2022-03-10 | |
| 2020-08-03 | $182.00K 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |